Assessment of bronchial hyperreactivity, maximal airway response and response to inhaled corticosteriod treatment in patients with bronchiectasis Source: Annual Congress 2007 - Current issues in airway physiology, pharmacology and monitoring Year: 2007
Dose reduction of inhaled corticosteroids under concomitant medication with montelukast in patients with asthma Source: Eur Respir J 2002; 20: 1080-1087 Year: 2002
Refractory asthmatics showing no bronchial reversibility with high-dose inhaled corticosteroids or β2 agonist inhalation: is this phenomenon airway remodeling? Source: Annual Congress 2007 - Improving asthma therapy - new findings in established and experimental treatment modalities Year: 2007
Dose response for inhaled fluticasone on airway and systemic inflammation in COPD Source: Annual Congress 2009 - Drug effects in COPD Year: 2009
Dose–response for inhaled fluticasone on airway and systemic inflammation in COPD Source: Eur Respir J 2011; 37: 206-209 Year: 2011
Effect of switching from high-dose inhaled corticosteroid (ICS) to low-dose ICS plus an inhaled long-acting β2 -agonist on asthma control, airway inflammation and remodeling, and gene expression in airway epithelial cells Source: Eur Respir J 2003; 22: Suppl. 45, 35s Year: 2003
Inhaled corticosteroids and growth of airway function in asthmatic children Source: Eur Respir J 2004; 23: 861-868 Year: 2004
Airway inflammation in COPD after long-term withdrawal of inhaled corticosteroids Source: Eur Respir J, 49 (6) 1700848; 10.1183/13993003.00848-2017 Year: 2017
Airway inflammation in COPD after long-term withdrawal of inhaled corticosteroids Source: Eur Respir J 2017; 49(1): 1600839; DOI: 10.1183/13993003.00839-2016 Year: 2017
Effect of the addition of montelukast on airway inflammation and remodeling in symptomatic asthma Source: International Congress 2017 – Asthma: mechanisms and treatment Year: 2017
Changes in objective markers following inhaled corticosteroids (ICS) in asthmatics with airway hyperresponsiveness (AHR) to mannitol Source: International Congress 2019 – Airway physiology Year: 2019
Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatment Source: Eur Respir J 2006; 27: 964-971 Year: 2006
Budesonide prevents but does not reverse sustained airway hyperresponsiveness in mice Source: Eur Respir J 2008; 32: 970-978 Year: 2008
Monitoring of inflammatory changes in patients with bronchial asthma before and after oral corticosteroid treatment Source: Annual Congress 2008 - Novel experimental approaches to understanding asthma and COPD II Year: 2008
Inhaled budesonide suppresses airway and systemic eosinophilic inflammation in COPD. No predictive value of a prednisolone test treatment Source: Eur Respir J 2005; 26: Suppl. 49, 290s Year: 2005
Short-term treatment with sistemic corticosteroids blunted neutrophilic airway response to ozone in mild asthmatics Source: Eur Respir J 2002; 20: Suppl. 38, 569s Year: 2002
Effects of budesonide/formoterol maintenance therapy on airway hyperresponsiveness and inflammation in an allergic rat model Source: Eur Respir J 2004; 24: Suppl. 48, 351s Year: 2004
Pulmonary function test changes after cessation of inhaled corticosteroid therapy in asthma patients Source: Annual Congress 2012 - Aspects of clinical asthma Year: 2012
Inhibition of allergen-induced airway remodelling by tiotropium and budesonide: a comparison Source: Eur Respir J 2007; 30: 653-661 Year: 2007
Influence of formoterol alone and its fixed combination with budesonide on airway responsiveness and airway inflammation induced by repeated low dose allergen challenge Source: Eur Respir J 2007; 30: Suppl. 51, 749s Year: 2007